Status:
COMPLETED
Blood Biomarker of Alzheimer's Disease (AD)
Lead Sponsor:
Duke University
Conditions:
Alzheimer Disease
Eligibility:
All Genders
50+ years
Brief Summary
Currently, no cures or disease modifying therapies exist for Alzheimer's disease (AD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are ...
Eligibility Criteria
Inclusion
- Alzheimer's Disease Patients:
- 50 years and older
- AD patient who is seen at the Memory Disorders Clinic
- AD diagnosis
- Non smoking
- No cancer treatment in the last 5 years
- Informed consent from the patient or the patient's legally authorized representative (LAR)
- Patient and/or LAR able to read and speak English
- Healthy Control Participants:
- 50 years and older
- Non smoking
- No cancer treatment in the last 5 years
- Age matched to AD subject
- Able to read and speak English
Exclusion
- Alzheimer's Disease Patients:
- Known additional neurological disease
- Healthy Control Participants:
- Neurological degenerative diseases (such as Parkinson's, Alzheimer's or Huntington's)
Key Trial Info
Start Date :
March 12 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2019
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT03340571
Start Date
March 12 2018
End Date
July 31 2019
Last Update
October 23 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University
Durham, North Carolina, United States, 27710